Integumen is an AIM-listed health care company. The group has a vertical integration business model and conjoining their Labskin technology platform with several artificial intelligence partners, medical devices, clinical research and life science. The healthcare company combines therapeutic operational expertise with data analytics to offer solutions to its clients, ranging from regulatory approvals to marketing precisely tested ingredients. Its Labskin platform facilitates healthcare, pharmaceuticals producers and cosmetic companies to test their products on human-like skin in a real-world environment and offers complete access to a range of state-of-art partner technologies. The group’s base station is located in Dublin, Northern Ireland. With the outstanding market capitalisation of £22.25 mn, the group is ranked in the small-cap companies listed on the London Stock Exchange and a constituent of FTSE AIM All-Share and FTSE AIM All-Share – Personal & Household Goods. ISPartners Investment Solutions AG and Peel Hunt are some of the major institutional investors in the group. (Source: Thomson Reuters)
On June 20-2019, in a company filing made by the company at 07:10 AM GMT, the company notified the appointment of Mr Paul Ryan as Enterprise Sales Head at Labskin AI. In the previous experiences of Mr Paul, he has rendered his services to companies like Microsoft, IBM, Siemens and Accenture and 8 West consulting.
Just before he got appointed by Integumen, he was working with 8 West Consulting, where he was managing a team of 240 personnel as Head of New Business Development. Also, he has rendered his services to the clients like Avon, Image Skincare, Estee Lauder and Anthem Inc.
The group also mentioned that they have appointed Mr Coli O’Sullivan as Chief Information Officer of the group. Before joining Integumen, he was employed with the Australian Medical Association and was responsible for transforming an online business segment of the Australian Medical Association.
In the same company filing, the group also addressed that post acquisition of RinoCloud and integration of their data management and analytic services into Labskin AI, and the group has occupied a new office in Cork, Ireland to centralise Integumen’s global IT operations.
Post this announcement made by the group as on June 20, 2019, its shares surged by 6.8 per cent at the London Stock Exchange and ended the session at GBX 2.42.
Recently (as on May 28, 2019), the Integumen group awarded three Labskin AI contracts, including one Cannabidiol, infused tampons to relieve cramp. The total value of contracts secured by the company stood at £290,000, and individual contracts were ranging from £35,000 to £210,000. The group also reported that revenue from the contracts as mentioned above, would come in the current financial year.
As on May 21, 2019, the group reported its trading update for the year ended December 31, 2018. Integumen recorded a strong performance in FY18, with revenue leapt by 111 per cent to £502k from £238k in the year-ago period. Also, revenue from the continued operation jumped by 294 per cent to £274k, driven by Labskin test kit revenue moves to full skin-care product test services.
In the FY18, group’s EBITDA losses narrowed by 12 per cent to £1.25 mn from a loss of £1.40 mn recorded in the year-ago period, and this was primarily on account of cost efficiency achieved under the new management in the last four months of the FY18.
The group also took specific strategic measures to mitigate indebtedness of the company like disposal of Visible Youth Group, Debt conversion, Cellulac debt conversion and Litigation issues. The group raised around £2.75 mn of which £232k was Vendor sale to allow 100 per cent acquisition of the RinoCloud Ltd.
During the year under review, the group disposed of TSPro GmbH, which saved £1.19 mn in current and future liabilities.
As on May 10, 2019, the group notified the exchange about the execution of the Labskin human clone skin testing platform. Besides this, the group also stated that Labskin AI platform could perform a double number of skin tests with accuracy and reliability than human beings can alone. Its AI backed platform provides real-time feedback to the client, which gives fast results, minimise development costs and reduce time to market.
Share Price Performance
Daily Price Chart (as on June 21, 2019), before the market close. (Source: Thomson Reuters)
At the time of writing (before the market close, at 12:51 PM GMT), shares of the SKIN were trading at GBX 2.35 and declined by 2.47 per cent against the previous closing price. As on April-05-2017, its shares got admitted to the Alternative Investment Market of the London Stock Exchange for trading.
The 5-day average daily shares exchanged hands were stood at 12,392,054.60, which was around 49.37 per cent below the 30-day average daily volume exchanged hands at the London Stock Exchange. Today’s volume in the stock stood at 11,557,181 with 96 trades took place at the London Stock Exchange (before the market close).
52wk H/L range
In the past 52-wks, shares of the SKIN have registered a high price of GBX 2.62 and a low price of GBX 0.35, and at the current trading level, as quoted in the price chart, shares were quoting around 591 per cent above the 52w low price level.
Price Performance (%)
On a YoY basis, shares of the SKIN have delivered a price return of 183 per cent and surpassed the benchmark index by approximately 174.42 per cent over the same period. However, on a year-to-date basis, the stock has recorded a price return of approximately 388.89 per cent and was up by around 28 per cent in the past one month.
Simple Moving Average (SMA)
From the Simple Moving Average standpoint, shares were quoting almost 100 per cent above the 200-day simple moving average price and also quoting above its 60-day and 30-day SMA prices as well.
Relative Strength Index (RSI)
The 30-day and 14-day relative strength index was strengthening the upside price movement as they are hovering in a neutral zone despite a significant surge in the price over the last one month.
At the current trading level, the stock took a reversal towards the 20-day SMA of the Bollinger Band®, which indicates that the stock could correct in the near-term. As after three consecutive days of a rising streak, the stock corrected around 2.4 per cent in today’s market session, before the market close.
Despite a humongous rise in the stock price over the past couple of weeks, the RSI still hovering at a position where it is strengthening the further upside movement in the stock price. However, a reversal in the stock price in today’s session indicates that the price could correct several points in near-term. The stock was carrying a Beta of 0.86, which indicates lower volatility between the stock and the benchmark index. Therefore, one should try to gauge out the future movement in the SKIN stock price based on the movements in the benchmark indices.
However, overall prospects in the stock look promising as management also stated that the group would continue to register strong performance for the financial year 2019, both organically and through acquisitions exercised at the end of the previous financial year.